cbdMD (NYSEAMERICAN:YCBD) Issues Earnings Results

cbdMD (NYSEAMERICAN:YCBD) issued its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, FiscalAI reports. cbdMD had a negative net margin of 10.64% and a negative return on equity of 51.76%. The firm had revenue of $5.02 million for the quarter.

cbdMD Price Performance

Shares of NYSEAMERICAN:YCBD traded up $0.08 during midday trading on Tuesday, reaching $0.78. 1,608,220 shares of the company’s stock were exchanged, compared to its average volume of 1,601,967. The company’s 50 day simple moving average is $1.08 and its two-hundred day simple moving average is $0.92. cbdMD has a 12 month low of $0.47 and a 12 month high of $3.96.

Insider Buying and Selling

In other cbdMD news, major shareholder Clark R. Crosnoe sold 550,701 shares of cbdMD stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $2.32, for a total transaction of $1,277,626.32. Following the sale, the insider directly owned 17,875 shares of the company’s stock, valued at approximately $41,470. The trade was a 96.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On cbdMD

An institutional investor recently bought a new position in cbdMD stock. Jane Street Group LLC acquired a new position in cbdMD, Inc. (NYSEAMERICAN:YCBD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 51,141 shares of the company’s stock, valued at approximately $69,000. Jane Street Group LLC owned approximately 0.49% of cbdMD as of its most recent filing with the Securities and Exchange Commission (SEC). 7.18% of the stock is owned by institutional investors and hedge funds.

cbdMD Company Profile

cbdMD, Inc (NYSEAMERICAN: YCBD) is a Charlotte, North Carolina–based producer and distributor of hemp-derived cannabidiol (CBD) products. Since its founding in 2018, the company has focused on developing a diverse portfolio of wellness offerings designed for human and pet use. Its product range includes tinctures, capsules, gummies, topicals, and pet-specific formulations, each developed to comply with U.S. Food and Drug Administration (FDA) guidelines for hemp-derived substances.

The company operates a vertically integrated business model, sourcing U.S.-grown hemp and overseeing manufacturing processes in cGMP-certified facilities.